Ribavirin: adverse drug reactions, 1986 to 1988
Respiratory syncytial virus (RSV) is the most common lower respiratory pathogen in United States children less than 2 years of age. Ribavirin, a synthetic nucleoside, is active in vitro against a broad spectrum of viruses, including RSV, and was approved for clinical use in the United States in Janu...
Gespeichert in:
Veröffentlicht in: | The Pediatric infectious disease journal 1990-03, Vol.9 (3), p.209-211 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Respiratory syncytial virus (RSV) is the most common lower respiratory pathogen in United States children less than 2 years of age. Ribavirin, a synthetic nucleoside, is active in vitro against a broad spectrum of viruses, including RSV, and was approved for clinical use in the United States in January, 1986. We reviewed the cumulative United States clinical experience with this antimicrobial agent from January 1, 1986, to September 30, 1988, by a detailed review of patient records from eight major hospitals with significant ribavirin experience. We also reviewed all adverse drug experience reports submitted to the Department of Health and Human Services during this time period. |
---|---|
ISSN: | 0891-3668 1532-0987 |
DOI: | 10.1097/00006454-199003000-00013 |